Company intelligence / Profile preview
Deutsche Biotech Innovativ AG
Hennigsdorf, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Develops antibody-based therapies like Adrecizumab for septic shock (completed preclinical, Phase I planned ~2015); small molecule DB1RA for breast cancer prevention (preclinical); AB2302 for cancer (preclinical). No recent clinical results reported post-2015 plans.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- AntibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Large pharmaceutical company (AB2302)
Beyond the preview
Go deeper on Deutsche Biotech Innovativ AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deutsche Biotech Innovativ AG.